Clinical trials: Breast Neoplasms, Triple-Negative
HR+ HER2- Metastatic Breast Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Triple Negative Breast Cancer, Male Breast Cancer
A Study of PF-06873600 in People With Cancer
The purpose of this clinical trial is to learn about the safety and effects of study medicine (PF-06873600) when taken alone or with hormone therapy by people with cancer.
- Trial name
- NCT03519178
- Testing
- PF-06873600, Endocrine Therapy 1, Endocrine Therapy 2
- Where
- 54 sites in United States, Bulgaria and 4 more
- Volunteers
- 155 people
- Sponsor
- Pfizer
Advance Solid Tumors
A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors
This is a 2-part, first-in-human, open-label study to determine the safety and tolerability of KIVU-107, a PTK7-directed antibody-drug conjugate, in participants with locally advanced or metastatic solid tumors.
- Trial name
- NCT07229313
- Testing
- KIVU-107
- Where
- 7 sites in United States, Australia
- Volunteers
- 76 people
- Sponsor
- Kivu Bioscience Inc.
Healthy Volunteers (Intended Indication: Metastatic Patients With Triple Negative or HR+ Breast Cancer, or Hormone Sensitive Prostate Cancer)
A Study to Assess How Itraconazole Affects the Uptake and Elimination of Capivasertib in the Body
This study will be an open-label, fixed sequence study in healthy subjects (vasectomized males and females of non-childbearing potential), performed at a single study centre.
- Trial name
- NCT04712396
- Testing
- Capivasertib, Itraconazole
- Where
- Germany
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Advanced Head and Neck Squamous Cell Carcinoma, Advanced Breast Cancer
A Study to Evaluate the Safety and Efficacy of CyPep-1 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic Cancers
This Phase 1b/2a study will assess the efficacy, safety, and pharmacodynamics of CyPep-1 when administered directly into measurable tumor lesions in combination with the anti-PD-1 antibody pembrolizumab.
- Conditions
- Advanced Head and Neck Squamous Cell Carcinoma, Advanced Breast Cancer, Advanced Melanoma
- Trial name
- Catalyst (NCT05383170)
- Testing
- CyPep-1, Pembrolizumab 25 MG/ML [KEYTRUDA®]
- Where
- 25 sites in United States, France and 3 more
- Volunteers
- 6 people
- Sponsor
- Cytovation AS
Triple Negative Breast Cancer, Breast Cancer
Preventive stRategy for IMMU132-relatED AEs in TNBC or Luminal Breast Cancer- PRIMED
This is a multicenter, open-label, single-arm, multicohort, two-stage optimal Simon's design, phase II clinical trial that is designed to improve the tolerance of sacituzumab govitecan in patients with unresectable locally…
- Conditions
- Triple Negative Breast Cancer, Breast Cancer, Advanced HR+/HER2- Breast Cancer
- Trial name
- PRIMED (NCT05520723)
- Testing
- Sacituzumab govitecan, Loperamide, Granulocyte Colony-Stimulating Factor
- Where
- 10 sites in Spain
- Volunteers
- 50 people
- Sponsor
- MedSIR
Breast Neoplasms, Triple-Negative, Breast Neoplasm Malignant Female
Olaparib & Radiation Therapy for Patients Triple Negative Breast Cancer (TNBC)
A Phase I of Olaparib with Radiation Therapy in Patients With Inflammatory, Loco-regionally Advanced or Metastatic TNBC (triple negative breast cancer) or Patient With Operated TNBC with Residual Disease.
- Conditions
- Breast Neoplasms, Triple-Negative, Breast Neoplasm Malignant Female, Radiotherapy Side Effect
- Trial name
- RadioPARP (NCT03109080)
- Testing
- Olaparib, Radiation therapy
- Where
- France
- Volunteers
- 24 people
- Sponsor
- Institut Curie
Imaging, Colorectal Cancer
A Phase 1, Multicenter Imaging Study of LNTH-2403 in Participants With Locally Advanced or Metastatic Solid Tumors.
LNTH-2403 (177Lu-DOTA-DUNP19) is a lutetium-177 radiolabeled, fully humanized monoclonal antibody (mAb) that binds with high specificity and affinity to leucine-rich repeat containing 15 (LRRC15), a transforming growth factor…
- Conditions
- Imaging, Colorectal Cancer, Head and Neck Squamous Cell Carcinoma, Non-Small Cell Lung Cancer
- Trial name
- DUNP19 (NCT07272642)
- Testing
- LNTH-2403
- Where
- Australia
- Volunteers
- 16 people
- Sponsor
- Radiopharm Theranostics, Ltd
Breast Cancer
ADCb (Anlotinib/Docetaxel/Carboplatin) as Neoadjuvant Therapy for Triple-Negative Breast Cancer
DCb (docetaxel/carboplatin) regimens as Neoadjuvant Treatment for Triple-Negative Breast Cancer have been recommended by NCCN guideline.Combination of anti-angiogenesis inhibitors is expected to further improvePathologic Complete…
- Trial name
- NCT04975451
- Testing
- Anlotinib
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Anqin Zhang
Triple -Negative Breast Cancer
Sacituzumab Tirumotecan in Neoadjuvant Treatment of Early-Stage TNBC
To explore the application of Sacituzumab Tirumotecan in neoadjuvant treatment of early-stage TNBC, a multicenter, Phase II clinical study of Sacituzumab Tirumotecan in neoadjuvant treatment of early-stage TNBC is proposed.
- Trial name
- NCT07007780
- Testing
- Sacituzumab Tirumotecan
- Volunteers
- 35 people
- Sponsor
- Xijing Hospital
Tubular Breast Cancer Stage II, Mucinous Breast Cancer Stage II
Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer
Study participants with primary breast cancer will receive a standard chemotherapy with an anthracycline and a taxane as well as trastuzumab in case of HER2-positive tumors at doses and duration in concordance to current…
- Conditions
- Tubular Breast Cancer Stage II, Mucinous Breast Cancer Stage II, Breast Cancer Female NOS, Invasive Ductal Breast Cancer
- Trial name
- GeparSixto (NCT01426880)
- Testing
- Carboplatin, background treatment
- Where
- 3 sites in Germany
- Volunteers
- 595 people
- Sponsor
- GBG Forschungs GmbH
Breast Cancer, Serplulimab Combined With SHR-A1811 as Neoadjuvant Therapy for Triple-Negative Breast Cancer
Serplulimab Combined With Trastuzumab Rezetecan as Neoadjuvant Therapy for Triple-Negative Breast Cancer
To evaluate the efficacy and safety of Serplulimab in combination with Trastuzumab Restuzumab for the neoadjuvant treatment of triple-negative breast cancer, aiming to provide evidence for optimizing the strategy of combining…
- Trial name
- NCT07466303
- Testing
- Serplulimab, SHR-A1811
- Where
- China
- Volunteers
- 84 people
- Sponsor
- Xijing Hospital
Clear Cell Renal Cell Cancer, Non-Small-Cell Lung Cancer
First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours
The purpose of this study is to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Antitumor Activity of AZD8701 Alone and in Combination with Durvalumab (MEDI4736) in Adult Subjects with…
- Conditions
- Clear Cell Renal Cell Cancer, Non-Small-Cell Lung Cancer, Triple Negative Breast Neoplasms, Squamous Cell Cancer of Head and Neck
- Trial name
- NCT04504669
- Testing
- AZD8701, Durvalumab
- Where
- 13 sites in United States, Canada and 2 more
- Volunteers
- 60 people
- Sponsor
- AstraZeneca
Breast Cancer
Adding Adjuvant Cisplatin and Gemicitabine Versus Capecitabine in Triple-negative Breast Cancer Patients in Non pCR After Neoadjuvant Standard Chemotherapy
In our study; investigator aim To show efficacy and toxicity of Adjuvant cisplatin and gemcitabine in triple-negative breast cancer patients with non pathologically complete response after neoadjuvant chemotherapy To compare…
- Trial name
- NCT06268327
- Testing
- Cisplatin injection and gemcitabine, Capecitabine tablets
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Assiut University
Triple Negative Breast Cancer
Study Evaluating Efficacy and Safety of SAR566658 Treatment in Patients With CA6 Positive Metastatic Triple Negative Breast Cancer
Primary Objective: To evaluate the tumor Objective Response Rate (ORR), according to the Response Evaluation Criteria in Solid Tumors (RECIST 1.1) of SAR566658 in participants with anti-carbonic anhydrase 6 (CA6)-positive…
- Trial name
- NCT02984683
- Testing
- SAR566658 (ACT14884)
- Where
- 13 sites in Belgium, Czechia and 3 more
- Volunteers
- 23 people
- Sponsor
- Sanofi
Solid Tumors, Triple-Negative Breast Cancer
Study of the Glutaminase Inhibitor CB-839 in Solid Tumors
Many tumor cells, in contrast to normal cells, have been shown to require the amino acid glutamine to produce energy for growth and survival.
- Conditions
- Solid Tumors, Triple-Negative Breast Cancer, Non Small Cell Lung Cancer, Renal Cell Carcinoma
- Trial name
- NCT02071862
- Testing
- CB-839, Pac-CB, CBE
- Where
- 13 sites in United States
- Volunteers
- 210 people
- Sponsor
- Calithera Biosciences, Inc
Advanced Melanoma, Triple-Negative Breast Cancer
Study of Imprime PGG and Pembrolizumab in Advanced Melanoma and Triple Negative Breast Cancer
Objective: To determine the Overall Response Rate (ORR) to Imprime PGG + pembrolizumab in subjects with advanced melanoma or metastatic TNBC Safety: To characterize the safety of Imprime PGG + pembrolizumab given in combination…
- Trial name
- NCT02981303
- Testing
- Imprime PGG, Pembrolizumab
- Where
- 10 sites in United States
- Volunteers
- 64 people
- Sponsor
- HiberCell, Inc.
Triple Negative Breast Neoplasms
Bintrafusp Alfa in High Mobility Group AT-Hook 2 (HMGA2) Expressing Triple Negative Breast Cancer
The main purpose of this study was to evaluate bintrafusp alfa monotherapy in participants with triple negative breast cancer (TNBC) who express high levels of HMGA2 as determined by a centralized reverse transcriptase-polymerase…
- Trial name
- NCT04489940
- Testing
- Bintrafusp alfa
- Where
- 45 sites in United States, Belgium and 4 more
- Volunteers
- 11 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Breast Cancer (Triple Negative Breast Cancer (TNBC)), Chemeotherapy
A Study of Tislelizumab Combined With TAC Regimen as Neoadjuvant Therapy for TNBC
To assess the efficacy and safety of tislelizumab combined with TAC as neoadjuvant therapy for triple-negative breast cancer, and to preliminarily investigate its underlying molecular mechanisms.
- Trial name
- NCT07827079
- Testing
- Nab paclitaxel/Carboplatin, anthracyclines,Tislelizumab
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Advanced Breast Carcinoma, Metastatic Breast Carcinoma
Onalespib and Paclitaxel in Treating Patients With Advanced Triple Negative Breast Cancer
This phase Ib trial studies the side effects and best dose onalespib when given together with paclitaxel in treating patients with triple negative breast cancer that has spread to other places in the body and usually cannot be…
- Conditions
- Advanced Breast Carcinoma, Metastatic Breast Carcinoma, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7
- Trial name
- NCT02474173
- Testing
- Laboratory Biomarker Analysis, Onalespib, Paclitaxel
- Where
- 4 sites in United States
- Volunteers
- 31 people
- Sponsor
- National Cancer Institute (NCI)
Triple Negative Breast Cancer, DNA Damage Repair Deficiency
Breast/Cyclosporin A/TNBC (Triple Negative Breast Cancer)
This will be a single arm, non-randomized, pre-surgical clinical trial of women with newly diagnosed triple negative breast cancer with high g-H2Ax (gamma H2AX antibodies) comparing changes in biomarkers from a diagnostic core…
- Trial name
- NCT06246786
- Testing
- Cyclosporin A
- Where
- United States
- Sponsor
- Virginia G. Kaklamani
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.